The combination of Janssen’s Galexos (simeprevir) and Gilead’s Sovaldi (sofosbuvir), for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease, has received a notice of compliance.
Receiving a notice of compliance allows the treatment to be sold in Canada with official approval. If a drug has a notice of compliance a doctor may prescribe the drug – but at this stage the new drug combination is still not available on public drug plans, like BC PharmaCare. At this stage private insurers each decide company coverage of the new drug (ie. what percentage of the drug costs they will cover).
Janssen’s Galexos has also been issued non-conditional approval for use in combination with peginterferon alfa and ribavirin for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease.
For more information about currently approved hep C treatments in BC, new and emerging drugs, the drug approval process in Canada and BC, or hep C support programs, please visit PHCN’s Hepatitis C Treatment Information Project or email firstname.lastname@example.org.